Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5MGI

Crystal structure of KPC-2 carbapenemase in complex with a phenyl boronic inhibitor.

Summary for 5MGI
Entry DOI10.2210/pdb5mgi/pdb
Related5ll7
DescriptorCarbapenem-hydrolyzing beta-lactamase KPC, (~{E})-3-[2-(dihydroxyboranyl)phenyl]prop-2-enoic acid (3 entities in total)
Functional Keywordscarbapenemase, beta-lactamase, phenyl boronic inhibitor, hydrolase
Biological sourceKlebsiella oxytoca
Total number of polymer chains1
Total formula weight28184.48
Authors
Vicario, M.,Celenza, G.,Bellio, P.,Perilli, M.G.,Tondi, D.,Cendron, L. (deposition date: 2016-11-21, release date: 2018-03-14, Last modification date: 2024-10-16)
Primary citationCelenza, G.,Vicario, M.,Bellio, P.,Linciano, P.,Perilli, M.,Oliver, A.,Blazquez, J.,Cendron, L.,Tondi, D.
Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPC-2: A Step against Bacterial Resistance.
Chemmedchem, 13:713-724, 2018
Cited by
PubMed Abstract: The emergence and dissemination of multidrug resistant (MDR) pathogens resistant to nearly all available antibiotics poses a significant threat in clinical therapy. Among them, Klebsiella pneumoniae clinical isolates overexpressing KPC-2 carbapenemase are the most worrisome, extending bacterial resistance to last-resort carbapenems. In this study, we investigate the molecular recognition requirements in the KPC-2 active site by small phenylboronic acid derivatives. Four new phenylboronic acid derivatives were designed and tested against KPC-2. For the most active, despite their simple chemical structures, nanomolar affinity was achieved. The new derivatives restored susceptibility to meropenem in clinical strains overexpressing KPC-2. Moreover, no cytotoxicity was detected in cell-viability assays, which further validated the designed leads. Two crystallographic binary complexes of the best inhibitors binding KPC-2 were obtained at high resolution. Kinetic descriptions of slow binding, time-dependent inhibition, and interaction geometries in KPC-2 were fully investigated. This study will ultimately lead toward the optimization and development of more-effective KPC-2 inhibitors.
PubMed: 29356380
DOI: 10.1002/cmdc.201700788
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.5 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon